Pivotal Testosil trial
Design
Phase II, n=120, 12 weeks, TT/FT primary, cortisol/VO2 secondary.
Endpoints
Primary: total testosterone; Secondary: free testosterone, AM cortisol, VO2max, PSQI.
Results
TT +22%, cortisol −18% vs placebo; improved PSQI; see full tables in the FR page.
Limitations
Single pivotal trial; population focused on mild hypogonadism; replication needed.
The gold-standard trial validation for Testosil's core matrix. A randomized, double-blind, placebo-controlled study (RCT) on 57 males (18-50 years).
Study Design
Conducted over 8 weeks. Subjects were naive to resistance training. Split into two groups: Placebo vs. 600mg KSM-66 Ashwagandha daily.
Key Outcome: Testosterone
+17% Increase in serum testosterone levels compared to placebo. This is statistically significant (p < 0.05) and correlates with subjective reports of vitality.
Secondary Outcomes
- Muscle Strength: Significant increase in 1-RM bench press.
- Recovery: Reduction in exercise-induced muscle damage (Creatine Kinase levels).
- Body Comp: Greater reduction in body fat percentage vs placebo.